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Background: The p53 tumor suppressor protein is a transcription factor that initiates transcriptional programs
aimed at inhibiting carcinogenesis. p53 represses metabolic pathways that support tumor development (such as
glycolysis and the pentose phosphate pathway (PPP)) and enhances metabolic pathways that are considered
counter-tumorigenic such as fatty acid oxidation.
Findings: In an attempt to comprehensively define metabolic pathways regulated by p53, we performed two
consecutive high-throughput analyses in human liver-derived cells with varying p53 statuses. A gene expression
microarray screen followed by constraint-based modeling (CBM) predicting metabolic changes imposed by the
transcriptomic changes suggested a role for p53 in enhancing gluconeogenesis (de novo synthesis of glucose).
Examining glucogenic gene expression revealed a p53-dependent induction of genes involved in both
gluconeogenesis (G6PC, PCK2) and in supplying glucogenic precursors (glycerol kinase (GK), aquaporin 3 (AQP3),
aquaporin 9 (AQP9) and glutamic-oxaloacetic transaminase 1 (GOT1)). Accordingly, p53 augmented hepatic glucose
production (HGP) in both human liver cells and primary mouse hepatocytes.
Conclusions: These findings portray p53 as a novel regulator of glucose production. By facilitating glucose export,
p53 may prevent it from being shunted to pro-cancerous pathways such as glycolysis and the PPP. Thus, our
findings suggest a metabolic pathway through which p53 may inhibit tumorigenesis.
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p53 is a transcription factor that regulates the expression of
many genes, thereby eliciting a myriad of cellular responses,
most of them culminate in an anti-tumorigenic effect [1].
Recently, the concept of p53 as a regulator of metabolism
has emerged with various metabolic pathways found to be
regulated by p53 in an anti-tumorigenic effort [2,3].
To comprehensively describe the effect of p53 on liver-
related metabolic pathways, we performed two consecutive
high-throughput analyses. We evaluated the global altera-
tions in gene expression in liver-derived HepG2 cells fol-
lowing two reciprocal manipulations in p53 status. First,
we down-regulated p53 levels in a group of HepG2 cells by
stably expressing short hairpin RNA targeting p53 (termed* Correspondence: goldstein.ido@gmail.com
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reproduction in any medium, provided the orHepG2sh-p53) while the control group expressed a non-
relevant short hairpin RNA (termed HepG2sh-con). Second,
we treated the cells with Nutlin-3a, a p53-activating agent,
resulting in accumulation of p53 protein levels and induc-
tion of p53-dependent transcriptional programs (Figure 1)
[4]. The transcriptome of HepG2 cells under the four dif-
ferent conditions was analyzed using gene expression
microarrays (as described in [4]). Next, we analyzed the
way these p53-dependent changes in the transcriptome are
predicted to affect metabolic pathways. This was done by
constraint-based modeling (CBM), a widely used computa-
tional method for studying metabolism on a genome-scale,
which has been successfully used for a variety of applica-
tions (Additional file 1 and [5]). Recently, two models of
human metabolism were published and their potential clin-
ical utility has been demonstrated [6,7]. The generic human
models have also served as a basis for generating context-
specific models including liver metabolic activities [8] andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 p53 protein level is elevated in HepG2 cells following
Nutlin-3a treatment. HepG2 cells were treated with the p53-
activating agent Nutlin-3a (10 μM) for 24 hours, total protein was
extracted and the protein level of p53 was analyzed in a western
blot analysis (as described in [13]). The presented data is a
representative experiment from more than three repeats.
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integrative metabolic analysis tool (iMAT), which inte-
grates the gene expression levels measured under different
conditions to predict a most-likely distribution of metabolic
fluxes, accounting for post-transcriptional flux activity pre-
dicted via stochiometric considerations [10,11]. We applied
iMAT to Nutlin-treated HepG2sh-con cells versus Nutlin-
treated HepG2sh-p53 cells. Performing pathway enrichment
analysis over the set of reactions predicted to be active in
each state, we found a significant enrichment of metabolic
reactions associated with gluconeogenesis in the Nutlin-
treated HepG2sh-con cells (P = 0.001, after correcting for
multiple hypothesis using false discovery rate (FDR) with
α = 0.05), while no enrichment was found for these path-
ways in the Nutlin-treated HepG2sh-p53 cells (for methods
summary see Additional file 2). In addition to gluconeo-
genesis, reactions in the fatty acid oxidation pathway were
also predicted to be active in p53-expressing cells. This
pathway was previously shown to be induced by p53 thus
attesting to the validity of our analysis [12]. A full list
of reactions predicted to be active or inactive following
alterations in p53 status is presented in Additional file 2:
Table S1.
Our analyses pointed to a role for p53 in regulating glu-
coneogenesis (de novo synthesis of glucose). Gluconeoge-
nesis is activated in hepatocytes when blood glucose levels
diminish (due to fasting or vigorous exercise), the glucose
is then secreted to the bloodstream thereby restoring glu-
cose homeostasis. Upon a hormonal stimulus the induction
of gluconeogenesis is achieved through transcriptional,
post-translational and allosteric alterations in four mainreactions of gluconeogenesis. These reactions are catalyzed
by the following enzymes: pyruvate carboxylase (PC),
phosphoenolpyruvate carboxykinase (PEPCK), fructose-1,
6-bisphosphatase (F1,6BPase) and glucose-6-phosphatase
(G6Pase). Transcriptional regulation of the genes encoding
these enzymes is crucial for an effective induction of gluco-
neogenesis [14]. Concomitantly with these alterations, the
liver is supplied with glucogenic precursors from extra-
hepatic tissues, which are converted to pyruvate and enter
the glucogenic pathway. The main precursors are lactate
and alanine (arriving from muscles during exercise) and gly-
cerol (arriving from adipocytes during lypolysis) (Figure 2).
Focusing on reactions associated with the gluconeogen-
esis pathway, we next evaluated the predicted flux rate car-
ried by each of these reactions in each condition. Strikingly,
three of the four regulated reactions in the gluconeogenesis
pathway (catalyzed by PC, PEPCK and G6Pase) were
predicted to carry higher metabolic flux in cells expressing
either basal or activated p53 than in any of the other states
(Figure 2 and Additional file 1: Table S1). Moreover, the
shuttling of glucose-6-phosphate (G6P) from the cytosol to
the endoplasmic reticulum (where G6P is dephosphory-
lated by G6Pase), which is essential for completion of glu-
coneogenesis, was predicted to carry higher metabolic flux
in p53-expressing cells than in HepG2sh-p53 (Figure 2 and
Additional file 1: Table S1).
In light of this prediction and in an attempt to find glu-
cogenic genes whose expression is altered in the presence
and activation of p53, we examined the expression levels
of several key gluconeogenesis-related genes using quanti-
tative PCR (qPCR). The mRNA levels of G6PC (encoding
the catalytic unit of G6Pase) and PCK2 (encoding mito-
chondrial PEPCK) were significantly elevated in Nutlin-
treated HepG2sh-con cells but not in Nutlin-treated
HepG2sh-p53 cells (Figure 3A). Moreover, several genes
whose encoded proteins participate in supplying glucogenic
precursors were elevated following Nutlin-3a treatment ex-
clusively in HepG2sh-con (aquaporin 3 (AQP3), aquaporin 9
(AQP9), glycerol kinase (GK) and glutamic-oxaloacetic
transaminase 1 (GOT1)). Notably, most of these genes par-
ticipate in the uptake and metabolism of glycerol into the
glucogenic pathway following lypolysis (AQP3, AQP9 and
GK; Figure 2).
In accordance with our in silico predictions and with
the p53-dependent changes in glucogenic gene expression,
we found that HepG2 cells exhibit increased hepatic glu-
cose production (HGP) following Nutlin-3a treatment
(Figure 3B). Moreover, primary hepatocytes isolated from
p53-deficient mice are impaired in their glucogenic cap-
acity compared to wild-type mice (Figure 3C). In order to
exclude any effects of cell viability affected by different
p53 statuses on total glucose levels, we normalized the
glucose level to total protein level yielding similar results
(Additional file 3: Figure S1). To summarize, we found
Figure 2 Activation of p53 is predicted to increase the flux through gluconeogenesis. The pathways supplying precursors to
gluconeogenesis and the glucogenic pathway are depicted. Red arrows represent the transcriptionally-regulated reactions of gluconeogenesis.
Bold arrows represent reactions predicted to carry higher flux in p53-expressing cells according to iMAT. Proteins whose genes are induced by
p53 are depicted in purple rectangles. DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde 3-phosphate, G6P, glucose-6-phosphate, iMAT,
integrative metabolic analysis tool; OAA, oxaloacetate; PEP, phosphoenolpyruvate.
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proteins are involved in both supplying glucogenic precur-
sors and gluconeogenesis. Accordingly, p53 promotes glu-
cose secretion in both human and mouse hepatocytes.
In combination with gene expression analysis, the iMAT
flux-prediction method can infer directionality of reactions
and metabolite production capacities. iMAT treats the ex-
pression levels of enzymes as cues for the likelihood that
their associated reactions carry metabolic flux. It then uses
network integration to accumulate these cues into a global,
consistent prediction of metabolic behavior. As such,
iMAT can reveal levels of post-transcriptional regulation
that are not reflected in the gene expression data. There-
fore, the proteins associated with reactions predicted to
carry higher flux are not necessarily regulated at the ex-
pression level and may be either regulated at the level of
translation or post-translationally. Moreover, the flux
through a certain reaction is calculated not only as a func-
tion of gene expression and regulation, but also with re-
spect to the sum of reactions in the cell and is therefore
affected by changes in expression of proteins not directly
associated with the reaction. Thus, iMAT is a reliable pre-
dictor of metabolic fluxes [10].
By employing iMAT, we were able to find a role for p53
in enhancing gluconeogenesis. Moreover, we found that p53
induces the expression of gluconeogenesis-related genes. As
a sequence-specific transcription factor, p53 mostly regu-
lates gene expression by binding to DNA regulatoryelements and enhancing transcription. In order to examine
the possibility that p53 directly regulates gluconeogenesis-
related genes, we utilized published data employing chro-
matin immunoprecipitation of p53 followed by massive
parallel sequencing (ChIP-seq) [16]. The p53 binding events
nearest to the genes’ transcription start site (TSS) were sev-
eral tens of kilobases away from the TSS and in most cases
(excluding GOT1) these binding events were closer to other
genes. This certainly does not exclude the possibility that
p53 regulates these genes by direct DNA binding, since it is
becoming evident that a transcription factor binding event
(including in the case of p53) is not necessarily responsible
for regulating the gene closest to it [17,18]. Moreover, the
ChIP-seq data is from non-hepatic cells which are not glu-
cogenic and the possibility exists that the chromatin around
gluconeogenesis-related genes in non-glucogenic cells is in-
accessible to transcription factor binding. Another plausible
scenario is that p53 regulates gluconeogenesis-related genes
in an indirect manner, namely through inducing the tran-
scription or the activity of a glucogenic transcription factor.
For example, p53 was found to augment the gene-inducing
activity of a known glucogenic transcription factor, gluco-
corticoid receptor (GR), (although the authors inspected the
effect of p53 on properties of GR that are not linked to glu-
coneogenesis) [19].
In accordance with the computational analysis and
the gene expression data, we found that p53 enhances
glucose production in both human and mouse
Figure 3 p53 enhances gluconeogenesis-related gene expression and augments hepatic glucose production (HGP). (A) HepG2 cells were
treated with the p53-activating agent Nutlin-3a (10μM) for 24 hours, total RNA was extracted and the mRNA levels of the indicated genes were
analyzed in qPCR analysis (as described in [4]). The primers used for qPCR are described in Additional file 1. (B) Densely-plated HepG2 cells were
incubated in glucogenic medium [15] for 24 hours. Glucose secretion to the media was measured by the glucose oxidase colorimetric method.
(C) Hepatocytes were isolated and incubated in gluconeogenic medium [15] for 4 hours. Glucose secretion to the media was measured by the
glucose oxidase colorimetric method. All presented data are representative experiments from at least three repeats. Each bar represents an
average of three triplicates. Columns marked with asterisks denote a significant (P <0.05) elevation, measured by a student’s t-test compared to
unmarked columns. qPCR, quantitative PCR.
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veral published data. First, p53 induces the expression of
TP53-induced glycolysis and apoptosis regulator (TIGAR),
which lowers the levels of fructose-2,6-bisphosphate
(F2,6BP), an inhibitor of gluconeogenesis [20]. Second,
p53 inhibits glucose-6-phosphate dehydrogenase (G6PD),
an enzyme that metabolizes G6P in the pentose phosphate
pathway (PPP) [21]. Thus, p53 may enhance gluconeogen-
esis by both increasing glucogenic flux due to lower
F2,6BP (resulting in higher G6P levels) and by blocking
the shunting of G6P to the PPP. Third, p53 forms acomplex with peroxisome proliferator-activated receptor
gamma coactivator 1 alpha (PGC1α), leading to modula-
tion of p53-dependent transcription [22]. The authors
also measured HGP as a general indicator of liver func-
tion. p53-deficient mice showed reduced glucogenic ca-
pacity compared with wild-type mice. PGC1α is an
important coactivator of gluconeogenic transcription fac-
tors [23] and the possibility exists that PGC1α directly
facilitates p53-dependent gluconeogenesis-related tran-
scription, leading to the observed improved HGP in wild-
type mice.
Goldstein et al. Cancer & Metabolism 2013, 1:9 Page 5 of 6
http://www.cancerandmetabolism.com//1/1/9Reduced G6Pase levels are correlated to the develop-
ment of hepatocellular carcinoma [24]. It has been postu-
lated that blocking the efflux of glucose to the bloodstream
leads to its shunting to other pathways which are consid-
ered pro-cancerous such as the PPP and glycolysis [25].
Thus, our finding that p53 induces G6PC expression and
enhances HGP adds another layer for the metabolic regu-
lation exerted by p53 in an effort to curtail carcinogenesis.
Availability of supporting data
The microarray results were deposited in GEO Acces-
sion Number GSE30137.
Additional files
Additional file 1: Detailed methods.
Additional file 2: iMAT analysis.
Additional file 3: Figure S1. Hepatocytes were isolated and incubated
in gluconeogenic medium [15] for 4 hours. Glucose secretion to the
media was measured by the glucose oxidase colorimetric method. The
glucose concentration was then normalized to total protein levels.
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